Files
Abstract
Acute myeloid leukemia (AML) is a form of blood cancer which mostly affects older people and undesirable outcomes of standard chemotherapy approaches are intolerable for this group of patients. Therefore, it is crucial to find more targeted and less toxic therapies for the treatment of AML. Tyrosine kinases have been shown as outstanding targets for novel targeted cancer therapies by numerous studies. In order to determine novel tyrosine kinase targets as functional drivers of leukemogenesis, our lab employed a functional RNAi-assisted target identification assay. Using this method, we screened a significant number of AML patient specimens against a panel of siRNA which targets every individual tyrosine kinase and then we recorded the impact on cell viability.